ClonaCell™-HY Medium A

Myeloma and hybridoma culture medium (serum-containing)
概要
ClonaCell™-HY Medium A is a serum-containing liquid medium formulated for the growth and expansion of parental myeloma cells prior to fusion and for the growth of stable hybridoma clones post-selection. This medium has been verified for use during mouse and rat hybridoma development and reportedly is compatible for production of hybridomas using lymphocytes from a variety of host animals including human, mouse, rat, and hamster.
Contains
• DMEM
• Serum
• Gentamicin
• 2-Mercaptoethanol
• Phenol red
• L-Glutamine and other supplements
• Other ingredients
Subtype
Specialized Media
Cell Type
Hybridomas
Species
Mouse
Application
Cell Culture, Hybridoma Generation
Brand
ClonaCell
Area of Interest
Antibody Development, Cell Line Development, Drug Discovery and Toxicity Testing, Hybridoma Generation
技术资料
数据及文献

Publications (1)

Cell 2019 may A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. S. Bangaru et al.

Abstract

Here, we describe the discovery of a naturally occurring human antibody (Ab), FluA-20, that recognizes a new site of vulnerability on the hemagglutinin (HA) head domain and reacts with most influenza A viruses. Structural characterization of FluA-20 with H1 and H3 head domains revealed a novel epitope in the HA trimer interface, suggesting previously unrecognized dynamic features of the trimeric HA protein. The critical HA residues recognized by FluA-20 remain conserved across most subtypes of influenza A viruses, which explains the Ab's extraordinary breadth. The Ab rapidly disrupted the integrity of HA protein trimers, inhibited cell-to-cell spread of virus in culture, and protected mice against challenge with viruses of H1N1, H3N2, H5N1, or H7N9 subtypes when used as prophylaxis or therapy. The FluA-20 Ab has uncovered an exceedingly conserved protective determinant in the influenza HA head domain trimer interface that is an unexpected new target for anti-influenza therapeutics and vaccines.
View All Publications
Top